scholarly journals THORACIC SURGERY Completion pneumonectomy and chemoradiotherapy as treatment options in local recurrence of non-small-cell lung cancer

2015 ◽  
Vol 1 ◽  
pp. 18-25
Author(s):  
Mariusz Kasprzyk ◽  
Grzegorz Sławiński ◽  
Martyna Musik ◽  
Łukasz Marciniak ◽  
Wojciech Dyszkiewicz ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Local Recurrence ◽  
Thoracic Surgery ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Options ◽  
Small Cell ◽  
Small Cell Lung ◽  
Completion Pneumonectomy

Current and evolving treatment options for limited stage small cell lung cancer

2006 ◽  
Vol 18 (2) ◽  
pp. 162-172 ◽  
Author(s):  
Carrie B Lee ◽  
David E Morris ◽  
Daniel B Fried ◽  
Mark A Socinski
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Options ◽  
Small Cell ◽  
Small Cell Lung ◽  
Limited Stage

Right non-small-cell lung cancer involving the atrium: VATS atriotomy and closure of the atrium using a running suture. VATS, video-assisted thoracic surgery

ASVIDE ◽  
2021 ◽  
Vol 8 ◽  
pp. 214-214
Author(s):  
Debora Brascia ◽  
Giulia De Iaco ◽  
Marcella Schiavone ◽  
Samuele Nicotra ◽  
Francesca Signore ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Thoracic Surgery ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Video Assisted Thoracic Surgery ◽  
Video Assisted

Treatment options for relapsed small-cell lung cancer

2007 ◽  
Vol 18 (3) ◽  
pp. 255-261 ◽  
Author(s):  
Hatem A. Azim ◽  
Apar Kishor Ganti
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Options ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Hao-chuan Ma ◽  
Yi-hong Liu ◽  
Kai-lin Ding ◽  
Yu-feng Liu ◽  
Wen-jie Zhao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adverse Events ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Options ◽  
Small Cell ◽  
Efficacy And Safety ◽  
Small Cell Lung ◽  
First Line ◽  
Grade 3

Abstract Background Whereas there are many pharmacological interventions prescribed for patients with advanced anaplastic lymphoma kinase (ALK)- rearranged non-small cell lung cancer (NSCLC), comparative data between novel generation ALK-tyrosine kinase inhibitors (TKIs) remain scant. Here, we indirectly compared the efficacy and safety of first-line systemic therapeutic options used for the treatment of ALK-rearranged NSCLC. Methods We included all phase 2 and 3 randomised controlled trials (RCTs) comparing any two or three treatment options. Eligible studies reported at least one of the following outcomes: progression free survival (PFS), overall survival (OS), objective response rate (ORR), or adverse events of grade 3 or higher (Grade ≥ 3 AEs). Subgroup analysis was conducted according to central nervous system (CNS) metastases. Results A total of 9 RCTs consisting of 2484 patients with 8 treatment options were included in the systematic review. Our analysis showed that alectinib (300 mg and 600 mg), brigatinib, lorlatinib and ensartinib yielded the most favorable PFS. Whereas there was no significant OS or ORR difference among the ALK-TKIs. According to Bayesian ranking profiles, lorlatinib, alectinib 600 mg and alectinib 300 mg had the best PFS (63.7%), OS (35.9%) and ORR (37%), respectively. On the other hand, ceritinib showed the highest rate of severe adverse events (60%). Conclusion Our analysis indicated that alectinib and lorlatinib might be associated with the best therapeutic efficacy in first-line treatment for major population of advanced NSCLC patients with ALK-rearrangement. However, since there is little comparative evidence on the treatment options, there is need for relative trials to fully determine the best treatment options as well as the rapidly evolving treatment landscape.

Outcomes of local thoracic surgery in patients with stage IV non–small-cell lung cancer: A SEER-based analysis

2021 ◽  
Vol 144 ◽  
pp. 326-340
Author(s):  
Jianlong Jia ◽  
Bin Guo ◽  
Zhiyi Yang ◽  
Yang Liu ◽  
Latai Ga ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Thoracic Surgery ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Stage Iv ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document